{"classes":[{"categories":[{"measurements":[{"comment":"Cannot be calculated because the participant was censored prior to the timepoint.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.2","upperLimit":"92.9","value":"53.6"},{"groupId":"OG001","lowerLimit":"76.0","upperLimit":"100","value":"91.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"comment":"Cannot be calculated because the participant was censored prior to the timepoint.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.7","upperLimit":"80.1","value":"57.9"},{"groupId":"OG001","lowerLimit":"49.3","upperLimit":"90.0","value":"69.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.2","upperLimit":"76.0","value":"70.1"},{"groupId":"OG001","lowerLimit":"71.3","upperLimit":"82.3","value":"76.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"249"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"100","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"More than one race"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.5","upperLimit":"100","value":"83.3"},{"groupId":"OG001","lowerLimit":"44.9","upperLimit":"100","value":"80.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Unknown for Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"287"},{"groupId":"OG001","value":"290"}],"units":"Participants"}],"description":"NIH-required analysis. Overall survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Analysis occurred after all participants had potentially been on study for at least 5 years. The distributions of survival times are compared, which is reported in the statistical analysis results. Five-year rates are provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy: 60 Gy intensity-modulated radiotherapy (IMRT), 2 Gy/day in 30 fractions (5 days a week for 6 weeks).","id":"OG000","title":"IMRT"},{"description":"Radiation therapy (RT): 60 Gy IMRT, 2 Gy/day in 30 fractions (5 days a week for 6 weeks).\n\nCetuximab: 400 mg/m\\^2 intravenously (IV) at least 5 days prior to IMRT; 250 mg/m\\^2 IV once a week for 6 weeks during RT and continuing 4 weeks after RT.","id":"OG001","title":"IMRT Plus Cetuximab"}],"paramType":"NUMBER","populationDescription":"Randomized eligible participants. Data were stratified by race.","reportingStatus":"POSTED","timeFrame":"From randomization to date of death or last follow-up. Maximum follow-up at time of analysis was 12.1 years.","title":"Percentage of Participants Alive (Overall Survival) by Race","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}